PCSK9 and hepatocellular carcinoma: Taken together, these results demonstrate the antitumor effect of flubendazole in HCC treatment by downregulating the PCSK9-induced Hh signaling pathway and indicate new therapeutic strategies and preclinical biomarkers for HCC diagnosis and treatment.